RxDoctor Payments DataLook up a doctor →

Rex Houser, MD

Neurology · Lacombe, LANPI 1184622110

Payments from drug & device makers

$14,272in general payments, 2019–2025

Across 881 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$903
  • Grifols USA, LLC$845
  • Acadia Pharmaceuticals Inc$836
  • Novartis$825
  • UCB, Inc.$781
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$1071%
  • Food & beverage$13,98798%
  • Education$1781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)130$1,701
Amgen(2 entities)54$903
Grifols USA, LLC49$845
Acadia Pharmaceuticals Inc52$836
Novartis71$825
UCB, Inc.43$781
Biogen44$611
SK Life Science, Inc.23$518
Lilly USA, LLC32$459
Sanofi27$453
Supernus Pharmaceuticals, Inc.28$415
Lundbeck LLC26$406
CSL Behring19$389
MDD US Operations, LLC16$379
Pfizer23$374
EMD Serono, Inc.13$318
Argenx US, Inc.13$280
Teva Pharmaceuticals USA, Inc.26$238
Biohaven Pharmaceuticals, Inc.12$233
Boston Scientific12$225
Acorda Therapeutics, Inc10$196
Nevro Corp.4$192
Genentech USA, Inc.10$180
Eisai Inc.10$173
AstraZeneca(2 entities)10$168
GE HealthCare8$166
Arbor Pharmaceuticals, Inc.11$147
Merz Pharmaceuticals, LLC8$142
Bristol Myers Squibb9$141
ANI Pharmaceuticals, Inc.6$125
Scilex Pharmaceuticals Inc.7$113
Adamas Pharmaceuticals, Inc.5$97
Neurocrine Biosciences, Inc.6$96
Saluda Medical Americas, Inc.1$96
Kyowa Kirin, Inc.5$90
Otsuka America Pharmaceutical, Inc.5$90
Jazz Pharmaceuticals Inc.5$85
Upsher-smith Laboratories LLC6$77
Alnylam Pharmaceuticals Inc.3$68
Johnson & Johnson4$62
Takeda Pharmaceuticals U.S.A., Inc.3$57
Sunovion Pharmaceuticals Inc.3$50
Abbott3$49
Tanabe Pharma America, Inc.3$47
Tersera Therapeutics LLC3$43
Neurelis, Inc.2$43
Ipsen Biopharmaceuticals, Inc1$33
Amneal Pharmaceuticals LLC2$31
Assertio Therapeutics, Inc.2$29
Avanir Pharmaceuticals, Inc.2$29
Sanofi-aventis U.S. LLC1$21
Mallinckrodt Hospital Products Inc.1$21
Promius Pharma LLC1$18
Avion Pharmaceuticals1$18
GRT US Holding, Inc.1$16
Harmony Biosciences LLC1$16
Collegium Pharmaceutical, Inc.1$15
Catalyst Pharmaceuticals, Inc.1$14
Almatica Pharma LLC1$14
Medtronic1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,272 in reported general payments places this provider in the 75th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$159,174
Medicare patients
195
Services billed
14,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate11$624,164
Avonex Pen (4 Pack)Interferon Beta-1a13$107,456
TecfideraDimethyl Fumarate11$102,227
BotoxOnabotulinumtoxina54$71,860
QuliptaAtogepant54$62,617
Dimethyl Fumarate36$53,607
Aimovig AutoinjectorErenumab-Aooe49$42,070
UbrelvyUbrogepant13$32,304
Emgality PenGalcanezumab-Gnlm24$30,893
RytaryCarbidopa/Levodopa14$22,226
NeuproRotigotine16$19,248
BriviactBrivaracetam13$17,927
Glatiramer Acetate11$15,251
Nurtec OdtRimegepant Sulfate15$13,635
VimpatLacosamide11$12,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$14$624,16411 claims
AbbVieBotox, Qulipta, Ubrelvy, Namzaric$1,701$174,025134 claims
BiogenTecfidera$611$102,22711 claims
UCB, Inc.Neupro, Briviact, Vimpat$781$49,73240 claims
Amneal Pharmaceuticals LLCRytary$31$22,22614 claims
PfizerNurtec Odt$374$13,63515 claims
Upsher-smith Laboratories LLCTopiramate$77$62953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 225 neurology providers in Louisiana.

Other neurology in Lacombe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →